299 related articles for article (PubMed ID: 11115167)
1. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability.
Ashcroft DM; Li Wan Po A; Williams HC; Griffiths CE
Arch Dermatol; 2000 Dec; 136(12):1536-43. PubMed ID: 11115167
[TBL] [Abstract][Full Text] [Related]
2. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
3. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Katz HI
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S62-8. PubMed ID: 9344188
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy.
Rim JH; Park JY; Choe YB; Youn JI
Am J Clin Dermatol; 2003; 4(7):507-10. PubMed ID: 12814339
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis.
Ashcroft DM; Po AL; Williams HC; Griffiths CE
BMJ; 2000 Apr; 320(7240):963-7. PubMed ID: 10753146
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
9. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
Lebwohl M; Yoles A; Lombardi K; Lou W
J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
[TBL] [Abstract][Full Text] [Related]
10. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and topical therapy.
Lebwohl M
Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
[TBL] [Abstract][Full Text] [Related]
12. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
Levine D; Even-Chen Z; Lipets I; Pritulo OA; Svyatenko TV; Andrashko Y; Lebwohl M; Gottlieb A
J Am Acad Dermatol; 2010 Nov; 63(5):775-81. PubMed ID: 20599292
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis: current perspectives with an emphasis on treatment.
Linden KG; Weinstein GD
Am J Med; 1999 Dec; 107(6):595-605. PubMed ID: 10625029
[TBL] [Abstract][Full Text] [Related]
14. Back to the future: a new topical approach for mild-to-moderate psoriasis.
Girolomoni G; Calzavara Pinton P; Cristaudo A; Cicchetti A
G Ital Dermatol Venereol; 2018 Jun; 153(3):375-382. PubMed ID: 27982547
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Lebwohl M; Colón LE
Cutis; 2007 Nov; 80(5 Suppl):29-40. PubMed ID: 18154221
[TBL] [Abstract][Full Text] [Related]
16. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
17. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Kin KC; Hill D; Feldman SR
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and systemic therapy.
van de Kerkhof P
Cutis; 2002 Nov; 70(5 Suppl):16-20. PubMed ID: 12467335
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
20. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
